Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.
US-based precision immunology drug developer ImmuneID completed a $50m series A round yesterday featuring Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities.
Life science-focused VC firm Alta Partners led the round, which included real estate investment manager Redwood Capital Investments, VC firm Section 32 and asset manager Tekla Capital Management.
The round also featured existing backers Arch Venture Partners, Longwood Fund, Pitango HealthTech and In-Q-Tel, the investment affiliate of the…
